Tovorafenib + Pimasertib for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing Tovorafenib, a drug that blocks proteins needed for cancer cell growth, in patients aged 12+ with hard-to-treat melanoma or other solid tumors.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have previously taken RAS- RAF-, MEK-, or ERK-directed inhibitor therapy, you may not be eligible for Substudy A.
What makes the drug Tovorafenib + Pimasertib unique for cancer treatment?
Tovorafenib (DAY101) combined with Pimasertib is unique because it targets specific pathways involved in cancer cell growth, potentially offering a novel approach for patients who may not respond to standard treatments. This combination may provide a new option for targeting cancer cells more effectively.12345
What data supports the effectiveness of the drug Tovorafenib + Pimasertib for cancer?
Are You a Good Fit for This Trial?
This trial is for people aged 12 and older with certain types of cancer, like melanoma or colorectal cancer, that have specific genetic changes in the MAPK pathway. They must have measurable disease progression and provide a tissue sample. It's not for those who've had prior treatment targeting the RAS-RAF-MEK-ERK pathway or have certain eye conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Tovorafenib is evaluated alone or in combination with other therapies to assess safety and efficacy
Safety Follow-up
Participants are monitored for safety after treatment
Long-term Follow-up
Survival status and subsequent anticancer therapies are collected
What Are the Treatments Tested in This Trial?
Interventions
- DAY101
- Pimasertib Hydrochloride
DAY101 is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Day One Biopharmaceuticals, Inc.
Lead Sponsor